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The reduced diameter of skeletal myofibres is a hallmark of several congenital myopathies, yet the underlying cellular and molecular
mechanisms remain elusive. In this study,we investigate the role ofHACD1/PTPLA, which is involved in the elongation of the very long
chain fatty acids, in muscle fibre formation. In humans and dogs, HACD1 deficiency leads to a congenital myopathy with fibre size dis-
proportionassociatedwithageneralizedmuscleweakness.ThroughanalysisofHACD1-deficientLabradors,Hacd1-knockoutmice, and
Hacd1-deficient myoblasts, we provide evidence that HACD1 promotesmyoblast fusion duringmuscle development and regeneration.
We further demonstrate that in normal differentiating myoblasts, expression of the catalytically active HACD1 isoform, which is
encoded by a muscle-enriched splice variant, yields decreased lysophosphatidylcholine content, a potent inhibitor of myoblast
fusion, and increased concentrations of ≥C18 and monounsaturated fatty acids of phospholipids. These lipid modifications correlate
with a reduction in plasma membrane rigidity. In conclusion, we propose that fusion impairment constitutes a novel, non-exclusive
pathological mechanism operating in congenital myopathies and reveal that HACD1 is a key regulator of a lipid-dependent muscle
fibre growth mechanism.
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Introduction
Congenital myopathies are rare hereditary diseases often charac-
terized by muscle weakness leading to physical motor impairment
that ranges from mild to life-threatening disabilities (North, 2008).
Several of these myopathies, including myotubular/centronuclear
myopathies (CNM) and other myopathies with congenital fibre
size disproportion, demonstrate early myofibre hypotrophy
(Jungbluth et al., 2008; North, 2008; Romero, 2010). However,
the underlying pathogenic mechanisms remain largely unknown.
In dogs and humans, 3-hydroxyacyl-CoA dehydratase 1 (HACD1)
deficiency has been associated with recessive congenital myop-
athies characterized by early-onset muscle weakness (Pele´ et al.,
2005; Muhammad et al., 2013). Early postnatal heterogeneity in
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myofibre size has been reported in both species, whereas progres-
sive nuclear centralization has been observed in diseased dogs, a
hallmark of CNM (Tiret et al., 2003). HACD1 encodes an endoplas-
mic reticulum (ER)-resident enzyme that interacts with ELOVL1-7,
KAR and TER proteins to form a complex involved in the synthesis
of very long chain fatty acids (VLCFAs) (Ikeda et al., 2008; Ohno
et al., 2010). As opposed to fatty acids up to C16, synthesized by
a cytosolic fatty acid synthase, the longer VLCFAs are elongated
within the ER in a four-step cycle (Kihara, 2012). In mammals,
four paralogous genes encoding HACD1-4 catalyse the third step
of this elongation cycle (Ikeda et al., 2008).
Following their incorporation into membrane lipids (such as
phospholipids and sphingolipids), VLCFAs elicit specific functions
based on their chain length and degree of unsaturation (Guillou
et al., 2010; Kihara,2012). In particular, they promote strong mem-
brane curvature and vesicle fusion (Schneiter et al., 2004; Molino
et al., 2014). In yeast, VLCFA elongation complex displays physical
interactions with the desaturase enzyme that catalyses the unsat-
uration of fatty acids (Miller et al., 2005), indicating interconnec-
tions between pathways involved in lipid balance. Although
Hacd1 deficiency was reported to impair myoblast growth and dif-
ferentiation in vitro (Lin et al., 2012), no molecular role for HACD1
has yet been reported in muscle cells.
We hypothesized that heterogeneity of muscle fibre size in
HACD1-related myopathies reflects a defect in muscle fibre devel-
opment, due to altered lipid balance. Muscle fibre development
occurs from embryogenesis through the early postnatal develop-
ment and can be recapitulated in adults following muscle injury.
During myofibre development, mononucleated precursor cells,
called myoblasts, differentiate through a well-defined process
(Buckingham, 2001; Bentzinger et al., 2012). Myoblasts are
derived from embryonic precursors or adult muscle satellite stem
cells and once activated, are committed to a myogenic programme
via a cascade of transcription factor activation that triggers myo-
blast fusion, leading to the formation of large, multinucleated myo-
fibres able to generate contractile force. A wealth of accumulated in
vivo data strongly suggests that myoblast fusion is a limiting step
for optimal myofibre growth, muscle mass, and regenerative cap-
acity (Horsley et al., 2001; Doherty et al., 2005; Georgiadis et al.,
2007; Laurin et al., 2008; Hochreiter-Hufford et al., 2013; Millay
et al., 2013, 2014; Lenhart et al., 2014). Similar to other processes
involving membrane fusion (Chernomordik and Kozlov, 2005),
myoblast fusion is the result of a complex interplay between
lipids and proteins, which specific roles are just now being unrav-
elled (Abmayr and Pavlath, 2012; Aguilar et al., 2013). A drop in
membrane rigidity, known to promote membrane fusion in other
cellular contexts (Maxfield and Tabas, 2005), is observed just
before myoblast fusion (Prives and Shinitzky, 1977), and modifica-
tions in membrane lipid composition, putatively yielding a raise in
membrane fluidity, have been reported during myoblast differenti-
ation (Nakanishi et al., 2001; Briolay et al., 2013). Giving further
support that lipids have an important role in regulating membrane
fusion, adding unsaturated fatty acids to the culture media that
purportedly increase membrane fluidity increases the capacity of
myoblasts to fuse (Prives and Shinitzky, 1977; Nakanishi et al.,
2001; Lee et al., 2009; Briolay et al., 2013). In contrast, lysopho-
sphatidylcholine, which inhibits lipid bilayer fusion due to its
inverted cone shape (Chernomordik and Kozlov, 2005), prevents
myoblast fusion when added to culture media (Leikina et al.,
2013). Altogether, these data suggest a model where naturally oc-
curring modifications of the lipid membrane composition and con-
comitant alterations in fluidity would play key role in myoblast
fusion. However, little is known regarding the genetic control of
these modifications; in addition, the physiological and clinical rele-
vance of modifications in composition and fluidity of myoblast
membrane has yet to be investigated.
Given the enzymatic function of HACD1 and its implication in
muscle homeostasis, we decided to address its precise role in
muscle fibre development in the light of its molecular properties.
We investigated this role by using combined in vitro and in vivo
experiments in mice and dogs.
Results
HACD1 is required for muscle fibre growth
HACD1 loss-of-function mutations have been associated with
congenital myopathies in humans and dogs (Pele´ et al., 2005;
Muhammad et al., 2013). To confirm the causative role of HACD1
deficiency in skeletal muscle impairment, we generated Hacd1-
knockout mice using a recombinant null allele inserting the LacZ
reporter gene (Supplementary Figure S1A–C). Heterozygous
mice for the knockout allele were morphologically and histologi-
cally indistinguishable from their wild-type littermates, in accord-
ance with the recessive inheritance pattern of HACD1 mutation in
human and dog (Pele´ et al., 2005; Muhammad et al., 2013); they
were used alongside wild-type mice as controls. In contrast, homo-
zygous mice for the knockout allele (hereafter Hacd12/2 mice),
although viable and fertile, presented a reduced body weight
gain after birth (Figure 1A). At 1 week of age, body weight of
Hacd12/2 mice was reduced by 14.6% compared with control
mice (P, 0.01). The reduced weight gain was never compensated
in adulthood despite a normal body size (Supplementary Figure
S1D), with a 15.2% and a 16.4% reduction in body weight at 12
weeks and 6 months of age compared with control mice, respect-
ively (P, 0.05 and P, 0.01, respectively). This reduction in
body weight could be more specifically attributed to a 29% reduc-
tion in muscle weight (Figure1B and C) and correlated with a27.5%
reduction in the muscle absolute maximal force compared with
controls (Figure 1D), however leaving specific maximal force
unchanged (Supplementary Figure S1E). In accordance with a dele-
terious muscle weakness, Hacd12/2 mice often displayed kypho-
sis (Supplementary Figure S1F).
This phenotype was reminiscent of that of HACD1-deficient
Labrador retrievers (hereafter HACD1cnm/cnm or CNM dogs) (Tiret
et al., 2003; Maurer et al., 2012). As for Hacd12/2 mice, CNM
dogs had reduced weight gain in the first weeks of life compared
with controls (Supplementary Figure S2A and B). Postural and loco-
motor weakness was obvious between 2 and 6 months of age and
histological analyses of skeletal muscles from 5-month-old CNM-
affected pups revealed that amyotrophy was accompanied by het-
erogeneity in muscle fibre diameter (Figure2A and B). Comparative
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studies between CNM dogs and Hacd12/2 mice (Figure 2A, B, E,
and F) revealed that in both cases, the mean myofibre diameter
was reduced by 29.7% and 22.3%, respectively (Figure 2C and G),
and the distribution of fibre diameters was shifted towards
smaller diameters in comparison with controls (Figure 2D and H);
in Hacd12/2 mice, the number of myofibres per muscle was
unchanged (Figure 2I), indicating that fibre hypotrophy per se
yielded the reduced muscle mass.
These data suggested an early requirement of HACD1 during
muscle development and an important role for muscle fibre growth.
Hacd1 is required for optimal myoblast fusion
In order to characterize the cause of the reduced muscle mass
and further discriminate between muscle atrophy and hypotrophy,
we recapitulated myofibre development during muscle regener-
ation in both dogs and mice. The course of regeneration was
similar in controls, CNM dogs and Hacd12/2 mice. Four to six
days after notexin-induced injury, massive muscle necrosis and cel-
lular infiltration were observed (Supplementary Figures S1G and
S2C), replaced on Day 15 by regenerating myofibres (Figure 3A,
B, D, E, G, H, and Supplementary Figure S2C). However, newly
formed myofibres were already significantly hypotrophic and the
largest myofibres were almost completely absent in CNM dogs
and Hacd12/2 mice (Figure 3C, F, I, and J), identifying myofibre
hypotrophy as a pathogenic mechanism. This reduced diameter
of fibres was still present on Day 30 and 90 of regeneration in
CNM dogs (Supplementary Figure S2C), indicating that no compen-
satory growth overcame this developmental defect. It is well-
accepted that a deficit in muscle fibre growth observed at this
stage of regeneration results from a defect in myoblast fusion
(Horsley et al., 2001; Doherty et al., 2005; Georgiadis et al.,
2007; Hochreiter-Hufford et al., 2013; Lenhart et al., 2014; Millay
et al., 2014). Accordingly, nuclear counts on Day 15 confirmed
that myofibres containing two nuclei were over-represented in
Hacd12/2 mice compared with controls, whereas myofibres with
7 nuclei (the highest number counted at this stage) were depleted
(Figure 3K).
To further confirm the impairment of myoblast fusion and deter-
mine if this defect was combined with a depletion in satellite cells,
we first assessed in mice muscles the number of Pax7-positive
satellite cells from which myoblasts differentiate to form new myo-
fibres. Both immunofluorescence and RT-qPCR experiments
Figure1Myopathy inHacd12/2mice. (A) Weight gain inHacd12/2,Hacd1+/2, and wild-type (WT) mice from birth to postnatal week3 (n ¼ 11,15,
and 12, respectively). (B) Photograph of gastrocnemius muscles from WT (left) and Hacd12/2 (right) 6-month-old mice. (C) Mean mass of gastro-
cnemius and tibialis anterior (TA) muscles from 6-month-old Hacd12/2, Hacd1+/2, and WT mice (gastrocnemius: n ¼ 5, 3, and 4 mice, respect-
ively; TA:n ¼ 9,7, and8mice, respectively). (D) Mean absolute maximal force of TA muscles fromHacd12/2,Hacd1+/2, and WT mice (n ¼ 16,12,
and 16, respectively). Error bars correspond to standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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indicated a similar expression ofPax7 inHacd12/2 mice compared
with controls (Supplementary Figure S3A–D), excluding reduced
numbers of satellite cells as causative of hypotrophy. We then
used the capacity of primary myoblasts isolated from young pups
to differentiate in vitro to characterize the contribution of Hacd1
in fusion. After 2 days of differentiation, cells isolated from
control and Hacd12/2 pups similarly formed myotubes and the
number of nuclei within myosin heavy chain-positive cells was
similar, indicating normal myoblast commitment into the differen-
tiation process (Figure 4A–C). In contrast, myotubes were globally
smaller in cultures from Hacd12/2 pups and presented a reduced
fusion index assessed by the average number of nuclei per
myotube (Figure 4A, B, and D). Accordingly, distribution of myo-
tubes with respect to their number of nuclei revealed fewer myo-
tubes with ≥6 nuclei, and greater numbers of small myotubes
with only 2 nuclei compared with controls (Figure 4E).
Together, these results demonstrate that both in dogs and mice,
Hacd1 function triggers the optimal fusion of myoblasts during
their differentiation, sustaining the normal growth of muscle
fibres within muscles.
The muscle-enriched Hacd1-fl isoform is upregulated during
muscle development and regeneration
During embryogenesis of Hacd1+/2 mice, strong expression of
the LacZ reporter gene was observed in heart and skeletal muscle
precursors (Figure 5A). LacZ expression was also highly induced
in adult skeletal muscles during injury-induced regeneration
(Figure 5B) and, more precisely, in regenerating myofibres recog-
nizable by the alignment of central nuclei (Figure 5C).
In wild-type dogs, two HACD1 splice variants are expressed in
normal skeletal muscles: the HACD1-fl full-length isoform retains
the seven exons of the gene whilst the HACD1-d5 isoform lacking
exon 5 encodes a truncated protein (Pele´ et al., 2005). RT-PCR con-
ditions designed to amplify both variants revealed a broad expres-
sion of the Hacd1-d5 isoform in mouse tissues (Figure 5D). In
contrast, Hacd1-fl expression was nearly restricted to the heart
and skeletal muscles, and in these tissues it was the predominant,
highly-expressed isoform. During mouse embryonic development,
a shift in Hacd1 splicing occurred between Day 7 and 17, with a
marked increase in Hacd1-fl expression at the expense of
Hacd1-d5 (Figure 5D). This embryonic period spans muscle fibre
maturation (Buckingham, 2001). To evaluate whether these two
variants would play specific dynamic roles during muscle growth,
we investigated by RT-(q)PCR their temporal expression during
in vitro differentiation of wild-type mouse primary or normal
C2C12 myoblasts. We observed that formation of myotubes fol-
lowed a marked upregulation of Hacd1-fl expression whereas
Hacd1-d5 expression was only mildly increased or did not change
in both primary myoblasts (Figure 5E and F) and C2C12
(Figure 5G and H). In vivo, Hacd1 was also markedly induced
during muscle regeneration, strengtheningHacd1-flpredominance
over Hacd1-d5 in muscles (Figure 5I). Expression of Hacd2 and
Figure 2 Defective myofibre growth in HACD1-deficient dogs and mice. (A andB) H&E-stained transverse sections of biceps femorismuscles from
5-month-old control (A) and HACD1cnm/cnm CNM-affected (B) dogs showing hypotrophic fibres in B. (C) Average myofibre diameter (inmm) in 3- to
4-year-old control andHACD1cnm/cnm dogs (n ¼ 3 for each genotype; ≥460fibres examined per dog). (D) Percent distribution by diameter (mm) of
myofibres analysed in C. (E and F) H&E-stained transverse sections of TA muscles from 3-month-old control (i.e. WT or Hacd1+/2 in E) and
Hacd12/2 (F) mice showing fibre size disproportion in F (n ¼ 3 for each condition). (G) Mean fibre diameter in TA muscles from 3-month-old
control and Hacd12/2 mice (n ¼ 3 for each group; ≥780 fibres per mouse). (H) Percent distribution by diameter (mm) of myofibres analysed in
G. (I) Mean number of total fibres in TA muscles from 3-month-old control and Hacd12/2 mice (n ¼ 5 for each group). Scale bar, 100 mm. Error
bars correspond to standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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Hacd3 did not change during differentiation (Supplementary
Figure S3E).
HACD1-FL is necessary for myoblast fusion
HACD1-FL protein is a vertebrate ortholog of the yeast enzyme
Phs1 and displays HACD activity (Ikeda et al., 2008). In addition,
we reported above a broad expression of Hacd1-d5 in mouse
tissues; besides, HACD1-167, an aberrant splice variant retaining
exons 1, 6, and 7, specifically accumulated in muscles from CNM
dogs (Pele´ et al., 2005). We thus investigated whether the two
HACD1-D5and HACD1-167proteins encoded by these isoforms, pre-
dicted respectively to exhibit two or three transmembrane domains
instead of the six identified in HACD1-FL (Supplementary Figure
S4A), shared cellular and molecular features with HACD1-FL. In myo-
genic cells, all three isoforms correctly localized to the ER. In
addition, HACD1-FL, HACD1-D5, HACD1-167, as well as HACD2,
HACD3, and HACD4 physically interacted with all other proteins of
the elongation complex, with the exception of HACD1-D5 that did
not interact with TER (Supplementary Figure S4B–D). In vitro, en-
zymatic assays revealed that HACD1-FL, but neither HACD1-D5 nor
HACD1-167, catalysed the dehydration of 3-hydroxypalmitoyl-CoA
into 2,3-trans-hexadecenoyl-CoA, in a dose-dependent manner
(Figure 6A and Supplementary Figure S4E). Accordingly, in vivo ex-
pression of HACD1-FL, but not HACD1-D5, HACD1-167, or
HACD1-FL-Y171A in which the Y171 essential residue (Kihara et al.,
2008) had been mutated, rescued cell growth arrest of
PHS1-shutdown yeasts (Figure 6B and Supplementary Figure S4F).
To decipher the relative functional importance of HACD1 iso-
forms during muscle cell differentiation, we stably knocked down
Hacd1 expression in C2C12 cells using a small hairpin interfering
RNA targeting the wild-type Hacd1-fl and Hacd1-d5 isoforms
(Supplementary Figure S5A). Myotube formation was severely
impaired inHacd1-knocked down (sh-Hacd1) cells (Figure6C), con-
firming previous data (Lin et al.,2012). Defective fusion events were
highlighted by a severe reduction in the number of nuclei per
sh-Hacd1 myotube, compared with controls (Figure 6C and D),
Figure 3Defective myoblast fusion in HACD1-deficient dogs and mice. H&E-staining of muscle transverse sections before (A andB) and on Day 15
after notexin injection (DandE) in control (AandD) andHACD1cnm/cnm (BandE) dogs. Scale bar,200 mm. (Cand F) Percent distribution by diameter
(mm) of myofibres from dog muscles before (C) and on Day15 after notexin injection (F) (n ¼ 1 for each genotype; ≥730 fibres examined per dog).
(GandH) Immunofluorescence for Dystrophin (green) on TA sections on Day15after notexin injection in control (G) andHacd12/2 (H) mice. Nuclei
are in blue. Scale bar, 100 mm. (I) Mean fibre diameter in TA muscles on Day 15 after notexin injection in control andHacd12/2 mice (n ¼ 3 and 4,
respectively;≥1780fibres per mouse). (J) Percent distribution by diameter (mm) of myofibres analysed in I. (K) Nuclear content of fibres (n ¼ 3 for
each group; ≥600 fibres per mouse). Error bars correspond to standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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although commitment of sh-Hacd1 cells into the differentiation
process was confirmed by increased expression of the Myogenin
and Myosin, heavy polypeptide 2, skeletal muscle, adult (Myh2)
myogenic markers (Supplementary Figure S5B–D) in line with the
phenotype of the Hacd12/2 myoblasts (Figure 4A and B). This
phenotype was thus consistent with our in vivo experiments that
revealed an impairment in myoblast fusion upon HACD1 deficiency.
To evaluate the function of each isoform, we transduced sh-
Hacd1 cells with retroviral vectors driving the expression of shRNA-in-
sensitive sequences encoding each of them (sh-Hacd1+isoform
cells) (Supplementary Figure S5E and F). Importantly, rescue of the
fusion impairment could be elicited only when the catalytically
active HACD1-FL isoform was expressed, demonstrating the essential
role of its specific activity in myoblast fusion (Figure 6C and D).
In parallel, sh-Hacd1 cells exhibited a reduced proliferation rate
(data not shown), as previously reported with the same interfering
sequence (Lin et al., 2012). However, in our hand, this phenotype
was neither rescued by HACD1-FL nor by HACD1-D5 and hence
likely resulted from an off-target effect of the RNA interference.
The fact that HACD1-FL could rescue the fusion defect without res-
cuing the proliferation defect further indicates that the proliferation
rate did not interfere with the fusion capacity of sh-Hacd1 cells.
HACD1-FL regulates lipid balance and membrane fluidity
To identify the putative HACD-dependent changes in lipid
content during myoblast differentiation, we compared phospho-
lipid fatty acid contents in proliferative C2C12 myoblasts, when
the Hacd1-fl to Hacd1-d5 ratio was the lowest, with those on Day
3 of differentiation, corresponding to 1 day after the peak of
Hacd1-fl expression (Figure 5G, H and Supplementary Figure S3E).
As lysophosphatidylcholine (LPC) acts as a potent inhibitor of
myoblast fusion when added to the differentiation medium
(Leikina et al., 2013), we first evaluated whether the relative
content of phospholipid species would be modified upon Hacd1
modulation (Supplementary Table S2). In control myoblasts, differ-
entiation was accompanied by a nearly two-fold drop in LPC that
was abolished in sh-Hacd1 myoblasts and fully restored in
sh-Hacd1+FL cells (Figure 7A and Supplementary Table S2A).
This global dynamic profile was underlain by the individual
profile of most LPCs (Supplementary Table S2B). This result demon-
strated that HACD1-FL activity is responsible for the drop in LPC
content preceding fusion. Myoblast differentiation was also accom-
panied by an increase in the level of phosphatidylinositols and a de-
crease in lysophosphatidylethanolamines that were independent of
Hacd1 expression (Supplementary Table S2A).
Figure 4Defective myoblast fusion in normally differentiating HACD1-deficient myoblasts. (A andB) Immunodetection on muscle primary cell cul-
tures from control or Hacd12/2 newborns on Day 2 of differentiation of the myosin heavy chains (MHC, green). Nuclei are in blue. Scale bar,
100 mm. (C) Unchanged differentiation index in HACD1-deficient myoblasts, i.e. percentage of nuclei contained in MHC-positive cells (n ¼ 5 for
each newborn group; ≥1000 nuclei per sample). (D) Decreased fusion index in HACD1-deficient myoblasts, i.e. average number of nuclei per
myotube (n ¼ 5 for each newborn group; ≥100 myotubes per sample). (E) Percent distribution of myotubes analysed in D by their number of
nuclei. Error bars correspond to standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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In parallel, we evaluated fatty acid content in the whole phospho-
lipid pool (Supplementary Table S3). As C18 species are the smal-
lest fatty acids produced by the VLCFA elongation complex (Ohno
et al., 2010), the ratio of C18-C26/C10-C16 fatty acids reflected
the elongation efficiency. Compared with controls, the ratio was
decreased in sh-Hacd1 cells both in proliferation and in differenti-
ation, and this elongation defect was alleviated by HACD1-FL
re-expression whereas it was amplified following HACD1-D5 ex-
pression (Figure 7B and Supplementary Table S3A and B). These
results confirmed a positive role of HACD1-FL in the elongation of
≥C18 fatty acids and revealed an antagonistic role for HACD1-D5.
Accordingly, the increase in theHacd1-fl toHacd1-d5 ratio reported
above indifferentiating controlmyoblasts was accompanied byan in-
crease in the C18-C26/C10-C16 ratio (Figure 7B and Supplementary
Table S3B).
Interactions between the yeast desaturase Ole1 and the VLCFA
elongation complex have been described (Miller et al., 2005). To
evaluate whether such an interaction could be conserved and
functional in mammals, we investigated the saturation status of
phospholipid fatty acids in myoblasts. Indeed differentiating
sh-Hacd1 myoblasts had an increased saturated fatty acid (SFA)
content, at the expense of monounsaturated fatty acids (MUFA)
Figure 5 Upregulation of the muscle-specific, Hacd1-full length (Hacd1-fl) isoform during muscle fibre development. (A and B) X-Gal staining of a
Hacd1+/2 embryo at E12.5 (A), TA muscles (B) from aHacd12/2mouse on Day15after injection of NaCl (left) or notexin (right). (C) Dissected fibres
from the notexin-injected muscle shown in B showing X-Gal staining in a regenerative fibre (centralized nuclei, in blue). Scale bar, 20 mm. (D)
RT-PCR experiments showing expression of Hacd1 transcripts in mouse tissues and embryos. (E–H) Expression of Hacd1 transcripts during differ-
entiation of primary muscle cells (E and F) and C2C12 cells (G and H) revealed by RT-PCR experiments (E and G) or RT-qPCR experiments (F and H)
showing fold-change from proliferation for each isoform (n ¼ 3 for each condition). (I) RT-qPCR experiments forHacd1-fl andHacd1-d5 isoforms in
TA muscles from wild-type mice, either non-injected (n ¼ 4) or on Day 6 (n ¼ 3) or Day 15 (n ¼ 4) after notexin injection. Error bars correspond to
standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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(Figure 7C and Supplementary Table S3C). Re-expression of
HACD1-FL fully restored normal SFA and MUFA contents and slight-
ly increased the polyunsaturated fatty acid (PUFA) content. During
proliferation too, HACD1-FL promoted MUFA accumulation at the
expense of SFA and HACD1-D5 isoform exhibited an antagonist
role (Supplementary Figure S6A and Table S3C).
Unsaturation of fatty acids contained in phospholipids is known
to increase fluidity of lipid bilayers (Maxfield and Tabas, 2005). To
check whether the altered contents of SFA, MUFA, and PUFA could
have a functional impact on myoblasts, we analysed their plasma
membrane fluidity on Day 3 of differentiation and found that it
was reduced by 9% in sh-Hacd1 cells at 378C (P ¼ 5.1025).
Fluidity was fully restored by HACD1-FL re-expression (Figure 7D
and Supplementary Figure S6B).
Discussion
We showed that HACD1-deficient mice and dogs exhibit an
early-onset hypotrophy of myofibres that could be recapitulated
during muscle regeneration after injury, two characteristics of myo-
blast fusion impairment (Horsley et al., 2001; Doherty et al., 2005;
Georgiadis et al., 2007; Laurin et al., 2008; Hochreiter-Hufford
et al., 2013; Millay et al., 2013, 2014; Lenhart et al., 2014).
Defective myoblast fusion upon HACD1 deficiency was confirmed
both in vivo and in vitro, as indicated by smaller myofibres contain-
ing fewer nuclei. Such an early phenotype could be the result of a
defect either in myoblast differentiation or in myoblast fusion per
se. On the contrary to previously published data (Lin et al.,
2012), we observed a normal commitment of both primary myo-
blasts and C2C12 cells into the differentiation upon Hacd1 defi-
ciency; in both cases, we reproducibly showed at the RNA and
protein levels that Hacd1 deficiency neither impaired Myogenin
and Myh2 expression nor reduced the proportion of cells positive
for MHC, a marker of terminal differentiation. This demonstrates
that myoblast fusion step was more specifically affected by
Hacd1 deficiency.
On the molecular level, we showed that during myoblast differ-
entiation, HACD1-FL activity prompts a drop in the content of
LPC, an inhibitor of myoblast fusion (Leikina et al., 2013). In paral-
lel, it promoted a slight increase in ≥C18 fatty acids, a rise in MUFA
content and a drop in plasma membrane rigidity. We propose a
Figure 6 Activity of HACD1 isoforms and role of HACD1-fl in myoblast fusion. (A) Affinity-purified 3×FLAG-tagged HACD1 isoforms incubated with
[14C]3-hydroxypalmitoyl-CoA (3-OH FA) and separated by normal-phase thin layer chromatography. (B) Shutdown ofPHS1 in a yeast strain carrying
PHS1 under control of a tetracycline (doxycycline; DOX)-dependent promoter leads to a lethal phenotype, rescued only by the active wild-type
HACD1-fl isoform. Cells were serially diluted at1:10. (C) On Day5of differentiation, sh-Hacd1 cells failed to form elongated myotubes, a phenotype
rescued only by re-expression of the wild-typeHACD1-fl (sh-Hacd1+fl) isoform. Scale bar,200 mm. (D) Fusion index of sh-Hacd1 cells and sh-Hacd1
cells re-expressing HACD1 isoforms (n ¼ 3 for each condition).
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model in which HACD1-FL upregulation during myoblast differenti-
ation modifies membrane lipid balance and its physical properties
to promote efficient fusion, eventually leading to optimal muscle
mass and force (Figure 7E).
In CNM dogs (Pele´ et al., 2005), exchange of wild-type HACD1
transcripts by those of the HACD1-167 isoform (which encodes
an inactive protein), mimics the human condition in which a non-
sense mutation abrogates the HACD activity of the encoded
protein (Muhammad et al., 2013). As the presence of small myofi-
bres is also observed in HACD1-deficient humans, we suggest that
defective myoblast fusion constitutes a novel, non-exclusive
pathological mechanism that participates to the reduction in
muscle mass and strength observed upon HACD1 deficiency.
More generally, myofibre heterogeneity with hypotrophic fibres
is an early feature of other myopathies with congenital fibre size
disproportion and CNM/MTM myopathies (Jungbluth et al., 2008;
North, 2008; Nance et al., 2012). Importantly, small fibre diameter,
but not the proportion of central nuclei, is associated with the most
severe MTM1 mutations and constitutes the worst outcome in
myotubular patients (Pierson et al., 2007). Hence we propose
that defective myoblast fusion might constitute a synergistic
pathogenic mechanism operating in these congenital myopathies
(Ravenscroft et al., 2015). If confirmed, a fusion defect would
have direct medical consequences, as it will be mandatory to envis-
age its early correction within the very first period of postnatal life.
Additional mechanisms underlying the accompanying concomitant
development of hypertrophic fibres in some cases of myopathies
with congenital fibre size disproportion (Jungbluth et al., 2008;
Muhammad et al., 2013), would also need to be assessed.
Importantly, no major cardiovascular phenotype could be observed
in HACD1-deficient young adult dogs and mice, which heart and
cardiovascular parameters were thoroughly evaluated using
Figure7HACD1 regulates lipid balance and membrane fluidity in myoblasts. (A) Lysophosphatidylcholine (LPC) content, expressed as the percent-
age of total phospholipids, in proliferation and on Day3of differentiation. (B) Ratio of C18-26 to C10-16phospholipid fatty acids in proliferation and
on Day 3 of differentiation. (C) Proportions of saturated (SFA), monounsaturated (MUFA), or polyunsaturated (PUFA) fatty acids on Day 3 of differ-
entiation. (D) Fluorescence anisotropy (r, inverse of fluidity) measured on Day3of differentiation. (E) Proposed model for the role ofHacd1-flduring
muscle fibre development. Error bars correspond to standard error of the mean. *P, 0.05, **P, 0.01, ***P, 0.001.
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electrocardiography, arterial blood pressure measurement, echo-
cardiography, and tissue-Doppler imaging (data not shown). Of
note, in contrast to skeletal muscles, heart development does
not rely on cell fusion events. This developmental difference may
contribute to protecting the heart from morbid consequences of
HACD1 deficiency; it also highlights the pathogenic role of fusion
impairment in skeletal muscles.
Changes in membrane fluidity and the degree of saturation of
membrane fatty acids each influence myoblast fusion (Prives and
Shinitzky, 1977; Nakanishi et al., 2001; Briolay et al., 2013). Our
results emphasize that Hacd1 may play a pivotal role in the inte-
grated genetic control of these previously reported changes, as
well as in the newly identified drop in LPC level. During myofiber de-
velopment, Hacd1-fl is upregulated and counteracts the Hacd1-d5
ubiquitous isoform that exerts an antagonistic role through a
still unknown mechanism. As a direct consequence of its 3-
hydroxyacyl-CoA dehydratase activity in the VLCFA elongation
complex (Ikeda et al., 2008), HACD1-FL promoted an increase in
the C18-C26 to C10-C16 ratio during myoblast differentiation. Our
data also revealed indirect key functions ofHacd1 that were not pre-
dicted by its HACD activity, which consist in an increased MUFA
content at the expense of SFA content and in a drop in both mem-
brane rigidity and LPC content. While there are growing evidences
of structural and functional interactions between enzymes of differ-
ent lipid pathways that we did not investigate in this study, our
results suggest a significant interplay of these pathways during
myoblast fusion and indicate that Hacd1 plays a key role in their
integrated regulation. These results also open novel medical
avenues, as manipulation of the complex Hacd1-dependent lipid
balance may represent an alternative, non-invasive therapeutic
strategy in HACD1-related or other congenital myopathies.
Although these changes might influence different steps of myo-
blast fusion such as myoblast migration or membrane merging,
they are all expected to favour membrane fusion per se. First, LPC
has been reported to inhibit several events of membrane fusion
(Reporter and Raveed, 1973; Chernomordik et al., 1993; Yeagle
et al., 1994; Ciechonska and Duncan, 2014), presumably
because its inverted cone-shape interferes with the negative mem-
brane curvature required for the hemifusion step (Chernomordik
and Kozlov,2005). Accordingly, LPC can reversibly inhibit myoblast
fusion, although its effect may depend upon its concentration and
the stage of fusion (Leikina et al., 2013; Teng et al.,2015). Our data
showed that Hacd1 regulates the LPC drop normally observed
during myoblast differentiation. We suggest that this drop in
total membranes increases myoblast permissiveness to fusion
and that the failure of this drop observed in Hacd1-deficient cells
constitutes a major determinant of myoblast fusion impairment
in HACD1-deficient conditions. Whether this LPC drop is of signifi-
cant importance for specific membrane compartments, including
the plasma membrane, will require further analyses. In parallel,
longer acyl chains of VLCFAs are proposed to fill the voids created
during membrane bending and to stabilize strong membrane curva-
tures (Schneiter et al., 2004; Chernomordik and Kozlov, 2005). Like
other fusion processes, myoblast fusion involves a hemifusion stage
for plasma membranes, during which lipids from the two merging
outer layers are mixed (Chernomordik and Kozlov, 2005; Leikina
et al., 2013), followed by the formation of a fusion pore inducing
cell content mixing. These two sequential steps necessitate
strong membrane curvature that would be favoured by VLCFAs, in
accordance with the defective vesicle fusion observed during cyto-
kinesis in plants lacking VLCFA-containing sphingolipids (Molino
et al., 2014). Finally, membrane fluidity is a well-known determinant
of successful membrane fusion (Maxfield and Tabas, 2005) and in
myoblasts, it could also promote fusion by concentrating
fusion-associated factors or lipid rafts at sites of contact between
activated myoblasts (Abmayr and Pavlath, 2012). During myoblast
differentiation, we showed that Hacd1 activation yields increased
levels of MUFAs at the expense of SFAs, a mechanism that likely par-
ticipates to the increased membrane fluidity and would explain the
enhanced myoblast fusion reported following addition of unsatur-
ated fatty acids, whereas saturated fatty acids or cholesterol, a mem-
brane rigidifier, tend to inhibit fusion (Prives and Shinitzky, 1977;
Nakanishi et al., 2001; Lee et al., 2009; Briolay et al., 2013).
In conclusion, the results presented here provide a unifying
genetic control accounting for several changes in lipid balance
that likely confer permissiveness for myoblast fusion in an additive
manner. This promoting function would result from the increase in
Hacd1-fl expression following a muscle-enriched splicing mechan-
ism. In addition to increasing the VLCFA content through its HACD
enzymatic activity, HACD1-FL would modify MUFA and LPC levels in-
directly, by regulating their respective biosynthetic pathways.
Desaturation of SFAs into MUFAs mostly relies on the desaturase
activity of ER-resident stearoyl-CoA desaturase proteins (Guillou
et al., 2010), and in yeast, physical interactions described
between the desaturase Ole1 and proteins of the VLCFA elongation
complex (Miller et al., 2005) suggest functional cross-talk between
the two enzymatic pathways. The LPC level results from a more
complex mechanism since it can be generated either by the cleav-
age of phosphatidylcholine by phospholipase A2 or by the
lecithin-cholesterol acyl-transferase activity. Interestingly, it has
been shown that increased LPC synthesis constitutes an important
step leading to atherosclerosis (Schmitz and Ruebsaamen, 2010).
LPC is also released by several tumour cell lines and because of
autotaxin activity, generates the potent cell motility activator lyso-
phosphatidic acid (Gotoh et al., 2012). Thus, identification of spli-
cing factors that upregulate Hacd1-fl and reduce LPC expression,
which is an issue in developmental myology, might be of wider
medical interest.
Further studies will be required to precisely assess the role of
Hacd1 on the metabolism, subcellular localization and function
of these candidate lipids, as well as on the indirect modulation of
pathways regulating LPC and unsaturated fatty acids contents.
Materials and methods
Mice and myoblasts
The Hacd1 knockout recombination vector (PRPGS00067_A_
B09) was obtained from the Knockout Mouse Project Repository
(KOMP; https://www.komp.org) and was electroporated into
C57BL/6N ES cells. All experiments were performed on mice gener-
ated from two independent ES clones. Matings between Hacd1+/2
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mice generated control (wild-type andHacd1+/2) andHacd1knock-
out (Hacd12/2) mice for all the described experiments.
The ANSES/EnvA/Upec Ethics Committee (C2EA – 16; www.
enseignementsup-recherche.gouv.fr) approved the experiments
performed on mice (approval numbers 11/11/15-2 and 20/12/
12-16).
sh-Hacd1 and control myoblasts were obtained by selecting
puromycin-resistant clones of C2C12 myoblasts, respectively
transfected with two different shRNA pGIPZ lentiviral vectors
against Hacd1 exon 4 or a control vector (OpenBiosystems).
Statistical analysis
A t-test-ANOVA with repeated measure factor was applied to
paired data, i.e. in the case of measurement of fibre number,
size, nuclear content, or PAX7-positive cell content on muscle sec-
tions, as well as mass measurements of paired muscles in mice.
Student’s t-test was used for all other analyses and Welch modifi-
cation was applied when sample number was low (n , 4). Data are
expressed as mean+ standard error of the mean and differences
were considered significative when P, 0.05.
Experimental details
Experimental details of regeneration experiments in dogs and
mice; immunological and histological staining; muscle section
analyses; tetanic force measurement; PCR, RT-PCR, and RT-qPCR
experiments; fluidity; HACD activity measurements; phospholipid
analyses; co-affinity purification experiments; additional ethics
statement are available in the Supplementary material.
Supplementary material
Supplementary material is available at Journal of Molecular Cell
Biology online.
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